- Home
- IVVD vs STRO Comparison
IVVD vs STRO Comparison
Compare IVVD & STRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IVVD
- STRO
- Stock Information
- Founded
- IVVD 2020
- STRO 2003
- Country
- IVVD United States
- STRO United States
- Employees
- IVVD N/A
- STRO N/A
- Industry
- IVVD Biotechnology: Pharmaceutical Preparations
- STRO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IVVD Health Care
- STRO Health Care
- Exchange
- IVVD Nasdaq
- STRO Nasdaq
- Market Cap
- IVVD 69.0M
- STRO 77.7M
- IPO Year
- IVVD 2021
- STRO 2018
- Fundamental
- Price
- IVVD $0.74
- STRO $0.76
- Analyst Decision
- IVVD Strong Buy
- STRO Hold
- Analyst Count
- IVVD 3
- STRO 7
- Target Price
- IVVD $5.85
- STRO $3.97
- AVG Volume (30 Days)
- IVVD 1.3M
- STRO 1.2M
- Earning Date
- IVVD 08-13-2025
- STRO 08-12-2025
- Dividend Yield
- IVVD N/A
- STRO N/A
- EPS Growth
- IVVD N/A
- STRO N/A
- EPS
- IVVD N/A
- STRO N/A
- Revenue
- IVVD $36,688,000.00
- STRO $66,434,000.00
- Revenue This Year
- IVVD $446.60
- STRO N/A
- Revenue Next Year
- IVVD $112.63
- STRO N/A
- P/E Ratio
- IVVD N/A
- STRO N/A
- Revenue Growth
- IVVD N/A
- STRO N/A
- 52 Week Low
- IVVD $0.35
- STRO $0.52
- 52 Week High
- IVVD $2.74
- STRO $5.17
- Technical
- Relative Strength Index (RSI)
- IVVD 48.03
- STRO 49.28
- Support Level
- IVVD $0.70
- STRO $0.73
- Resistance Level
- IVVD $0.77
- STRO $0.83
- Average True Range (ATR)
- IVVD 0.05
- STRO 0.06
- MACD
- IVVD -0.00
- STRO 0.01
- Stochastic Oscillator
- IVVD 45.94
- STRO 61.90
About IVVD Invivyd Inc.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.